arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Johnson & Johnson

JNJ Health Care Biotechnology: Pharmaceutical Preparations
$267.61
▲ +3.2% Today
as of Oct 22, 16:49 ET
Last 30 days +0.48% Sep 14 → Oct 22
$246.74 $253.51 $260.28 $267.05 $273.82 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$260.54
High
$269.67
Low
$259.04
Volume
$10M
Avg Vol
$8M
Mkt Cap
$622.8B
P/E (TTM)
39.14
Beta
—
52w High
$281.07
52w Low
$184.66
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 3 ● 22 ▼ 0
Oct 21 · 18:15 24/7 Wall St. neutral
Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
Oct 21 · 17:31 Insider Monkey neutral
Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?
Oct 21 · 17:19 Barrons.com neutral
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock
▸ Show all 25 press releases & news Free account →

JNJ earnings at a glance

The options market is pricing a move of about ±4.0% after the report, a range of roughly $256.97 to $278.25 from today's $267.61. Over its last 5 reports the stock rose the next day 2 times and fell 3, moving ±2.0% on average; after the most recent report on Jul 15, 2026 it moved -2.7%. That means options currently expect more movement than JNJ has typically delivered. JNJ beat the consensus EPS estimate in 5 of its last 5 reported quarters. Implied volatility is currently 34%. The share price of $267.61 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$185
$281
86% of range
Avg surprise (last 5)
+1.9%
Avg reaction (last 5)
+0.9%
40% positive
Latest IV / EM
34%
EM ±4.0% · $258 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.03$2.53$5.09$7.65$10.21 Actual $-0.03Actual $1.96Actual $10.21Actual $1.34Actual $1.93Actual $1.11Actual $4.54Actual $2.77Est $2.66Actual $2.80Est $2.77Actual $2.46Est $2.43Actual $2.70Est $2.67Actual $2.90Est $2.85 AprJulOctMarJunSepMarJun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$0$6.6B$13.3B$19.9B$26.6B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Wed Jul 15, 2026Jun/2026 $2.90 $2.85 +2.1% +2.9% -2.7% earnings
Tue Apr 14, 20268K 2026-04-14 $2.70 $2.67 +1.1% — +0.9% earnings
Wed Jan 21, 20268K 2026-01-21 $2.46 $2.43 +1.2% — -0.1% earnings
Tue Oct 14, 2025Sep/2025 $2.80 $2.77 +1.1% — -0.0% earnings
Wed Jul 16, 2025Jun/2025 $2.77 $2.66 +4.1% — +6.2% earnings
Sun Mar 30, 2025Mar 2025 $4.54 — — — — financials
Sun Sep 29, 2024Sep 2024 $1.11 — — — — financials
Sun Jun 30, 2024Jun 2024 $1.93 — — — — financials
Sun Mar 31, 2024Mar 2024 $1.34 — — — — financials
Sun Oct 1, 2023Oct 2023 $10.21 — — — — financials
Sun Jul 2, 2023Jul 2023 $1.96 — — — — financials
Sun Apr 2, 2023Apr 2023 $-0.03 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$25.31B$24.06B—$23.99B$23.74B$21.89B—$22.47B
Cost of revenue$8.05B$8.11B—$7.30B$7.63B$7.36B—$6.96B
Gross profit$17.26B$15.96B—$16.69B$16.11B$14.54B—$15.51B
Operating income————————
Net income$5.53B$5.24B—$5.15B$5.54B$11.00B—$2.69B
EPS (diluted)$2.27$2.14—$2.12$2.29$4.54—$1.11

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$20.42B$21.69B$19.71B$18.23B$18.58B$38.47B$24.11B$19.98B
Inventory$15.14B$14.58B$14.19B$14.15B$13.41B$12.66B$12.44B$12.60B
Total current assets$59.77B$59.17B$55.62B$54.61B$54.50B$71.55B$55.89B$53.25B
Total assets$201.06B$200.89B$199.21B$192.82B$193.39B$193.67B$180.10B$178.29B
Long-term debt$37.34B$37.53B$39.44B$39.41B$39.23B$38.35B$30.65B$31.29B
Total liabilities$116.09B$119.71B$117.67B$113.54B$114.92B$115.56B$108.61B$108.13B
Total equity$84.97B$81.19B$81.54B$79.28B$78.47B$78.11B$71.49B$70.16B

Implied volatility — last 90 days

22%28%34%40%46% Jun 07 — IV 27% · EM ±2.5%Jun 08 — IV 26% · EM ±2.2%Jun 09 — IV 30% · EM ±2.2%Jun 10 — IV 29% · EM ±1.7%Jun 11 — IV 35% · EM ±1.5%Jun 15 — IV 27% · EM ±1.9%Jun 16 — IV 26% · EM ±1.5%Jun 17 — IV 35% · EM ±1.5%Jun 19 — IV 25% · EM ±2.7%Jun 22 — IV 27% · EM ±2.2%Jun 23 — IV 28% · EM ±2.1%Jun 24 — IV 28% · EM ±1.7%Jun 25 — IV 22% · EM ±0.9%Jun 29 — IV 31% · EM ±5.5%Jun 30 — IV 31% · EM ±5.3%Jul 01 — IV 31% · EM ±5.2%Jul 02 — IV 35% · EM ±5.6%Jul 03 — IV 36% · EM ±5.6%Jul 06 — IV 37% · EM ±5.2%Jul 07 — IV 42% · EM ±5.5%Jul 08 — IV 38% · EM ±4.8%Jul 09 — IV 38% · EM ±4.5%Jul 10 — IV 34% · EM ±3.8%Jul 13 — IV 44% · EM ±3.7%Jul 14 — IV 46% · EM ±3.3%Jul 15 — IV 36% · EM ±2.1%Jul 16 — IV 34% · EM ±1.4%Jul 20 — IV 28% · EM ±2.3%Jul 21 — IV 28% · EM ±2.0%Jul 22 — IV 28% · EM ±1.7%Jul 23 — IV 35% · EM ±1.5%Jul 27 — IV 28% · EM ±2.3%Jul 28 — IV 32% · EM ±2.3%Jul 29 — IV 29% · EM ±1.7%Jul 30 — IV 33% · EM ±1.4%Aug 03 — IV 28% · EM ±2.3%Aug 04 — IV 33% · EM ±2.4%Aug 05 — IV 29% · EM ±1.7%Aug 06 — IV 32% · EM ±1.4%Aug 10 — IV 28% · EM ±2.3%Aug 11 — IV 24% · EM ±1.7%Aug 12 — IV 26% · EM ±1.5%Aug 13 — IV 25% · EM ±1.0%Aug 17 — IV 24% · EM ±2.0%Aug 18 — IV 27% · EM ±1.9%Aug 19 — IV 26% · EM ±1.5%Aug 20 — IV 29% · EM ±1.2%Aug 24 — IV 24% · EM ±2.0%Aug 25 — IV 25% · EM ±1.8%Aug 26 — IV 26% · EM ±1.5%Aug 27 — IV 31% · EM ±1.3%Aug 31 — IV 24% · EM ±2.0%Sep 01 — IV 25% · EM ±1.8%Sep 02 — IV 28% · EM ±1.7%Sep 03 — IV 25% · EM ±1.0%Sep 07 — IV 26% · EM ±2.2%Sep 08 — IV 29% · EM ±2.1%Sep 09 — IV 28% · EM ±1.6%Sep 10 — IV 26% · EM ±1.1%Sep 14 — IV 25% · EM ±2.1%Sep 15 — IV 29% · EM ±2.1%Sep 16 — IV 26% · EM ±1.5%Sep 17 — IV 25% · EM ±1.1%Sep 21 — IV 25% · EM ±2.1%Sep 22 — IV 27% · EM ±1.9%Sep 23 — IV 28% · EM ±1.7%Sep 24 — IV 26% · EM ±1.1%Sep 28 — IV 28% · EM ±5.0%Sep 29 — IV 29% · EM ±5.0%Sep 30 — IV 27% · EM ±4.6%Oct 01 — IV 28% · EM ±4.5%Oct 02 — IV 27% · EM ±4.2%Oct 05 — IV 26% · EM ±3.6%Oct 06 — IV 30% · EM ±3.9%Oct 07 — IV 32% · EM ±4.0%Oct 08 — IV 34% · EM ±4.0%

Sector peers

ABBV
AbbVie Inc.
$479.5B $285.19-1.4%
NVS
Novartis AG
$273.4B $156.27+1.7%
ABT
Abbott Laboratories
$170.8B $102.51+0.1%
NVO
Novo Nordisk A/S
$169.4B $39.43+0.2%
VRTX
Vertex Pharmaceuticals Incorporated
$128.2B $535.17+4.0%
SNY
Sanofi
$98.0B $41.96+1.4%

JNJ earnings FAQ

What is JNJ's expected move for earnings?

Options currently price a move of about ±4.0%, or $10.64 per share either way from $267.61.

How does JNJ stock usually react to earnings?

Across the last 5 reports the average next-day move was ±2.0%, up 2 times and down 3 times.

What is JNJ's implied volatility?

JNJ's at-the-money implied volatility is about 34% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in